Market closedADR
Amarin/$AMRN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amarin
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Ticker
$AMRN
Sector
Trading on
Industry
Biotechnology
Headquarters
Ireland, Ireland
Employees
-
Website
Amarin Metrics
BasicAdvanced
$175M
-
-$0.20
1.83
-
Price and volume
Market cap
$175M
Beta
1.83
52-week high
$1.11
52-week low
$0.35
Average daily volume
1.7M
Financial strength
Current ratio
3.309
Quick ratio
2.315
Long term debt to equity
1.589
Total debt to equity
1.99
Interest coverage (TTM)
-7,903.29%
Management effectiveness
Return on assets (TTM)
-4.56%
Return on equity (TTM)
-15.83%
Valuation
Price to revenue (TTM)
0.76
Price to book
0.36
Price to tangible book (TTM)
0.37
Price to free cash flow (TTM)
-5.598
Growth
Revenue change (TTM)
-25.51%
Earnings per share change (TTM)
33.33%
3-year revenue growth (CAGR)
-26.81%
3-year earnings per share growth (CAGR)
117.20%
What the Analysts think about Amarin
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Amarin stock.
Amarin Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Amarin Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Amarin News
AllArticlesVideos
Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance
Business Wire·2 weeks ago
![New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fn%2Fa%2Fp%2Fpress10-2975653.jpg&w=3840&q=75)
New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo
GlobeNewsWire·2 weeks ago
Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript
Seeking Alpha·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Amarin stock?
Amarin (AMRN) has a market cap of $175M as of April 05, 2025.
What is the P/E ratio for Amarin stock?
The price to earnings (P/E) ratio for Amarin (AMRN) stock is 0 as of April 05, 2025.
Does Amarin stock pay dividends?
No, Amarin (AMRN) stock does not pay dividends to its shareholders as of April 05, 2025.
When is the next Amarin dividend payment date?
Amarin (AMRN) stock does not pay dividends to its shareholders.
What is the beta indicator for Amarin?
Amarin (AMRN) has a beta rating of 1.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.